[68Ga]Ga-NOTA-AE105 uPAR-PET/MRI在原发性胶质瘤患者中的前瞻性II期试验:预后价值及对uPAR靶向放射性核素治疗的启示
这项前瞻性II期试验纳入24例疑似原发性胶质瘤患者,行动态60分钟[68Ga]Ga-NOTA-AE105 uPAR-PET/MRI,以肿瘤SUVmax与正常脑SUVmean比值≥2.0判定uPAR阳性。中位随访18.8个月时,高uPAR表达组的总生存期和无进展生存期均显著更差,多数胶质瘤尤其是WHO 4级者呈uPAR阳性。
要点
- 24例中67%为uPAR阳性,WHO 4级胶质瘤中94%为uPAR阳性。
- 高uPAR表达组总生存期HR 14.3(95%CI 1.8-112.3;P=0.011)。
- 高uPAR表达组无进展生存期HR 26.5(95%CI 3.3-214.0;P=0.0021)。
核心结论
- 多数胶质瘤患者及几乎所有WHO 4级胶质瘤患者呈uPAR阳性病灶,提示[68Ga]Ga-NOTA-AE105 PET/MRI在胶质瘤中可行。
- 高uPAR表达与患者更差的生存结局显著相关。
- uPAR阳性胶质瘤比例高,提示这些患者可能是uPAR靶向放射性核素治疗的潜在对象。
研究设计与样本
- 前瞻性II期临床试验,24例疑似原发性胶质瘤患者接受约200 MBq(范围83-222 MBq)[68Ga]Ga-NOTA-AE105后行动态60分钟PET/MRI。
- 以肿瘤SUVmax与正常脑SUVmean比值≥2.0判定为uPAR阳性病灶。
- 随访评估总生存期和无进展生存期,并依据肿瘤SUVmax分为高、低uPAR表达组。
主要发现
- 24例中16例(67%)为WHO 4级胶质瘤,6例(25%)为3级,2例(8%)为2级。
- 全部患者中67%呈uPAR阳性病灶,WHO 4级胶质瘤中94%呈uPAR阳性。
- 中位随访18.8(2.1-45.6)个月时,19例疾病进展、14例死亡。
- 高uPAR组总生存期HR 14.3(95%CI 1.8-112.3;P=0.011),无进展生存期HR 26.5(95%CI 3.3-214.0;P=0.0021)。
- uPAR表达作为连续变量时,总生存期HR 2.7(95%CI 1.5-4.8;P=0.0012),无进展生存期HR 2.5(95%CI 1.5-4.2;P=0.00073)。
关键数值与推荐
- uPAR阳性判定标准为肿瘤SUVmax与正常脑SUVmean比值≥2.0。
- 高uPAR组总生存期HR 14.3(95%CI 1.8-112.3;P=0.011)。
- 高uPAR组无进展生存期HR 26.5(95%CI 3.3-214.0;P=0.0021)。
- uPAR连续变量总生存期HR 2.7(95%CI 1.5-4.8;P=0.0012)。
- uPAR连续变量无进展生存期HR 2.5(95%CI 1.5-4.2;P=0.00073)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Treatment of patients with low-grade and high-grade gliomas is highly variable due to the large difference in survival expectancy. New non-invasive tools are needed for risk stratification prior to treatment. The urokinase plasminogen activator receptor (uPAR) is expressed in several cancers, associated with poor prognosis and may be non-invasively imaged using uPAR-PET. We aimed to investigate the uptake of the uPAR-PET tracer [68Ga]Ga-NOTA-AE105 in primary gliomas and establish its prognostic value regarding overall survival (OS), and progression-free survival (PFS). Additionally, we analyzed the proportion of uPAR-PET positive tumors to estimate the potential number of candidates for future uPAR-PRRT. METHODS: In a prospective phase II clinical trial, 24 patients suspected of primary glioma underwent a dynamic 60-min PET/MRI following the administration of approximately 200 MBq (range: 83-222 MBq) [68Ga]Ga-NOTA-AE105. Lesions were considered uPAR positive if the tumor-to-background ratio, calculated as the ratio of TumorSUVmax-to-Normal-BrainSUVmean tumor-SUVmax-to-background-SUVmean, was ≥ 2.0. The patients were followed over time to assess OS and PFS and stratified into high and low uPAR expression groups based on TumorSUVmax. RESULTS: Of the 24 patients, 16 (67%) were diagnosed with WHO grade 4 gliomas, 6 (25%) with grade 3, and 2 (8%) with grade 2. Two-thirds of all patients (67%) presented with uPAR positive lesions and 94% grade 4 gliomas. At median follow up of 18.8 (2.1-45.6) months, 19 patients had disease progression and 14 had died. uPAR expression dichotomized into high and low, revealed significant worse prognosis for the high uPAR group for OS and PFS with HR of 14.3 (95% CI, 1.8-112.3; P = 0.011), and HR of 26.5 (95% CI, 3.3-214.0; P = 0.0021), respectively. uPAR expression as a continuous variable was associated with worse prognosis for OS and PFS with HR of 2.7 (95% CI, 1.5-4.8; P = 0.0012), and HR of 2.5 (95% CI, 1.5-4.2; P = 0.00073), respectively. CONCLUSIONS: The majority of glioma patients and almost all with grade 4 gliomas displayed uPAR positive lesions underlining the feasibility of 68Ga-NOTA-AE105 PET/MRI in gliomas. High uPAR expression is significantly correlated with worse survival outcomes for patients. Additionally, the high proportion of uPAR positive gliomas underscores the potential of uPAR-targeted radionuclide therapy in these patients. TRAIL REGISTRATION: EudraCT No: 2016-002417-21; the Scientific Ethics Committee: H-16,035,303; the Danish Data Protection Agency: 2012-58-0004; clinical trials registry: NCT02945826, 26Oct2016, URL: https://classic. CLINICALTRIALS: gov/ct2/show/NCT02945826 .
引用
- Azam A, Kurbegovic S, Carlsen EA, et al. Prospective phase II trial of [68Ga]Ga-NOTA-AE105 uPAR-PET/MRI in patients with primary gliomas: Prognostic value and Implications for uPAR-targeted Radionuclide Therapy. EJNMMI Res. 2024. PMID: 39472354. doi:10.1186/s13550-024-01164-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。